CN103301447A - DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用 - Google Patents
DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用 Download PDFInfo
- Publication number
- CN103301447A CN103301447A CN2013102560889A CN201310256088A CN103301447A CN 103301447 A CN103301447 A CN 103301447A CN 2013102560889 A CN2013102560889 A CN 2013102560889A CN 201310256088 A CN201310256088 A CN 201310256088A CN 103301447 A CN103301447 A CN 103301447A
- Authority
- CN
- China
- Prior art keywords
- dna
- mtx
- cell
- pkcs
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010059866 Drug resistance Diseases 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title abstract description 180
- 108020004414 DNA Proteins 0.000 title abstract description 25
- 229960000485 methotrexate Drugs 0.000 title abstract description 10
- 102000053602 DNA Human genes 0.000 title abstract 4
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 claims abstract description 137
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 claims abstract description 137
- 230000004544 DNA amplification Effects 0.000 claims abstract description 53
- 230000008859 change Effects 0.000 claims abstract description 20
- 101150074155 DHFR gene Proteins 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 abstract description 250
- 230000014509 gene expression Effects 0.000 abstract description 49
- 230000003321 amplification Effects 0.000 abstract description 23
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 23
- 101150085823 hsdR gene Proteins 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 21
- 230000010261 cell growth Effects 0.000 abstract description 8
- 230000006907 apoptotic process Effects 0.000 abstract description 7
- 108010022394 Threonine synthase Proteins 0.000 abstract description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 101710132601 Capsid protein Proteins 0.000 abstract description 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 47
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 45
- 108020001096 dihydrofolate reductase Proteins 0.000 description 45
- 238000000034 method Methods 0.000 description 36
- 230000035945 sensitivity Effects 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 239000000284 extract Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 238000001262 western blot Methods 0.000 description 18
- SPCMQFLNOVTUBM-UHFFFAOYSA-N [7-(dimethylazaniumyl)-10h-phenothiazin-3-yl]-dimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=C([NH+](C)C)C=C2SC3=CC([NH+](C)C)=CC=C3NC2=C1 SPCMQFLNOVTUBM-UHFFFAOYSA-N 0.000 description 16
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 102100027828 DNA repair protein XRCC4 Human genes 0.000 description 14
- 101000649315 Homo sapiens DNA repair protein XRCC4 Proteins 0.000 description 14
- 238000013459 approach Methods 0.000 description 14
- 238000001556 precipitation Methods 0.000 description 13
- 102100037700 DNA mismatch repair protein Msh3 Human genes 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 101001027762 Homo sapiens DNA mismatch repair protein Msh3 Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 101000759188 Homo sapiens Zinc finger FYVE domain-containing protein 16 Proteins 0.000 description 11
- 102100023385 Zinc finger FYVE domain-containing protein 16 Human genes 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 11
- KKTZALUTXUZPSN-UHFFFAOYSA-N 2-(4-morpholinyl)-4-benzo[h][1]benzopyranone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1N1CCOCC1 KKTZALUTXUZPSN-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000007901 in situ hybridization Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229950010131 puromycin Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102100034533 Histone H2AX Human genes 0.000 description 5
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 5
- 101000804921 Homo sapiens X-ray repair cross-complementing protein 5 Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 description 5
- 210000002230 centromere Anatomy 0.000 description 5
- 230000016507 interphase Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 238000003153 stable transfection Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 101150010856 CRT gene Proteins 0.000 description 4
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 4
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 239000006481 glucose medium Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011337 individualized treatment Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010060248 DNA Ligase ATP Proteins 0.000 description 2
- 102100033195 DNA ligase 4 Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000009668 clonal growth Effects 0.000 description 2
- 238000013377 clone selection method Methods 0.000 description 2
- 235000019628 coolness Nutrition 0.000 description 2
- -1 covered (20 * 20) Substances 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000000887 face Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102100036883 Cyclin-H Human genes 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 description 1
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710161408 Folylpolyglutamate synthase Proteins 0.000 description 1
- 102100035067 Folylpolyglutamate synthase, mitochondrial Human genes 0.000 description 1
- 101710200122 Folylpolyglutamate synthase, mitochondrial Proteins 0.000 description 1
- 108010093223 Folylpolyglutamate synthetase Proteins 0.000 description 1
- 108050007570 GTP-binding protein Rad Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100025945 Glutaredoxin-1 Human genes 0.000 description 1
- 101000713120 Homo sapiens Cyclin-H Proteins 0.000 description 1
- 101000856983 Homo sapiens Glutaredoxin-1 Proteins 0.000 description 1
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710155795 Probable folylpolyglutamate synthase Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710151871 Putative folylpolyglutamate synthase Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102000002114 Reduced Folate Carrier Human genes 0.000 description 1
- 108050009454 Reduced Folate Carrier Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000005886 chromosome breakage Effects 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150033380 dnapkcs gene Proteins 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 102000030722 folylpolyglutamate synthetase Human genes 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310256088.9A CN103301447B (zh) | 2013-06-25 | 2013-06-25 | DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310256088.9A CN103301447B (zh) | 2013-06-25 | 2013-06-25 | DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103301447A true CN103301447A (zh) | 2013-09-18 |
CN103301447B CN103301447B (zh) | 2014-12-31 |
Family
ID=49127453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310256088.9A Active CN103301447B (zh) | 2013-06-25 | 2013-06-25 | DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103301447B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104480111A (zh) * | 2014-09-18 | 2015-04-01 | 南通大学附属医院 | 一种逆转肝癌细胞多药耐药的shRNA及其应用 |
CN104946755A (zh) * | 2015-06-11 | 2015-09-30 | 哈尔滨医科大学 | Brca1蛋白在制备逆转肿瘤细胞对mtx耐药性的药物中的应用 |
CN104962523A (zh) * | 2015-08-07 | 2015-10-07 | 苏州大学张家港工业技术研究院 | 一种测定非同源末端连接修复活性的方法 |
CN106492217A (zh) * | 2016-10-31 | 2017-03-15 | 哈尔滨医科大学 | Parp1抑制剂在制备逆转肿瘤细胞对氨甲蝶呤耐药性药物中的应用 |
CN109200288A (zh) * | 2018-09-14 | 2019-01-15 | 哈尔滨医科大学 | Msh3蛋白抑制剂在制备逆转mtx耐药肿瘤细胞耐药性的药物中的应用 |
CN109289051A (zh) * | 2018-09-14 | 2019-02-01 | 哈尔滨医科大学 | Msh2抑制剂在制备逆转mtx耐药肿瘤细胞耐药性的药物中的应用 |
CN112210541A (zh) * | 2020-10-14 | 2021-01-12 | 上海市普陀区利群医院 | 一种胃肠道间质瘤耐药细胞模型及其构建方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001096574A1 (fr) * | 2000-06-13 | 2001-12-20 | Otsuka Pharmaceutical Co., Ltd. | Nouveau gene enzymatique et son produit d'expression |
WO2003005964A2 (en) * | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
-
2013
- 2013-06-25 CN CN201310256088.9A patent/CN103301447B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001096574A1 (fr) * | 2000-06-13 | 2001-12-20 | Otsuka Pharmaceutical Co., Ltd. | Nouveau gene enzymatique et son produit d'expression |
WO2003005964A2 (en) * | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
Non-Patent Citations (1)
Title |
---|
RURORA ET AL: "Gene amplification in human cells knocked down for RAD54", 《GENOME INTEGRITY》 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104480111A (zh) * | 2014-09-18 | 2015-04-01 | 南通大学附属医院 | 一种逆转肝癌细胞多药耐药的shRNA及其应用 |
CN104946755A (zh) * | 2015-06-11 | 2015-09-30 | 哈尔滨医科大学 | Brca1蛋白在制备逆转肿瘤细胞对mtx耐药性的药物中的应用 |
CN104946755B (zh) * | 2015-06-11 | 2017-07-11 | 哈尔滨医科大学 | Brca1蛋白在制备逆转肿瘤细胞对mtx耐药性的药物中的应用 |
CN104962523B (zh) * | 2015-08-07 | 2018-05-25 | 苏州大学 | 一种测定非同源末端连接修复活性的方法 |
CN104962523A (zh) * | 2015-08-07 | 2015-10-07 | 苏州大学张家港工业技术研究院 | 一种测定非同源末端连接修复活性的方法 |
CN106492217B (zh) * | 2016-10-31 | 2018-12-28 | 哈尔滨医科大学 | Parp1抑制剂在制备逆转肿瘤细胞对氨甲蝶呤耐药性药物中的应用 |
CN106492217A (zh) * | 2016-10-31 | 2017-03-15 | 哈尔滨医科大学 | Parp1抑制剂在制备逆转肿瘤细胞对氨甲蝶呤耐药性药物中的应用 |
CN109200288A (zh) * | 2018-09-14 | 2019-01-15 | 哈尔滨医科大学 | Msh3蛋白抑制剂在制备逆转mtx耐药肿瘤细胞耐药性的药物中的应用 |
CN109289051A (zh) * | 2018-09-14 | 2019-02-01 | 哈尔滨医科大学 | Msh2抑制剂在制备逆转mtx耐药肿瘤细胞耐药性的药物中的应用 |
CN109289051B (zh) * | 2018-09-14 | 2021-01-08 | 哈尔滨医科大学 | Msh2抑制剂在制备逆转mtx耐药肿瘤细胞耐药性的药物中的应用 |
CN109200288B (zh) * | 2018-09-14 | 2021-05-18 | 哈尔滨医科大学 | Msh3蛋白抑制剂在制备逆转mtx耐药肿瘤细胞耐药性的药物中的应用 |
CN112210541A (zh) * | 2020-10-14 | 2021-01-12 | 上海市普陀区利群医院 | 一种胃肠道间质瘤耐药细胞模型及其构建方法和应用 |
CN112210541B (zh) * | 2020-10-14 | 2022-11-15 | 上海市普陀区利群医院 | 一种胃肠道间质瘤耐药细胞模型及其构建方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103301447B (zh) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103301447B (zh) | DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用 | |
CN106492217B (zh) | Parp1抑制剂在制备逆转肿瘤细胞对氨甲蝶呤耐药性药物中的应用 | |
CN104531620A (zh) | 肺癌干细胞条件3d培养方法 | |
CN103898057B (zh) | 一种顺铂耐药骨肉瘤u2os细胞系及其制备方法 | |
CN104946755B (zh) | Brca1蛋白在制备逆转肿瘤细胞对mtx耐药性的药物中的应用 | |
CN106434864A (zh) | 肿瘤标志物limk1及其应用 | |
CN109825587B (zh) | 一种胶质瘤预后标志物cpvl及其应用 | |
CN109971851A (zh) | MiR-125b-2-3p作为鉴别诊断肾癌亚型的分子标志物及其在肿瘤转移中的用途 | |
CN109321656A (zh) | 蛋白depdc1作为诊断三阴乳腺癌的标记物的用途 | |
CN102168085A (zh) | 抑制miR-130b基因表达的siRNA和表达载体及其在制备提高肝癌治疗效果的药物中的应用 | |
CN103920164A (zh) | MiR-424-5p在抑制转移性肝癌中的应用 | |
CN107488735B (zh) | miR-339-5p在抑制前列腺癌骨转移及TGF-β信号通路中的应用 | |
CN102391372B (zh) | 一种肝癌药物治疗的靶标及其应用 | |
CN104758287A (zh) | 细胞周期依赖激酶1的特异性酶活性抑制剂ro-3306的用途 | |
CN109929844B (zh) | 一种胶质瘤预后标志物cpvl抑制剂及其应用 | |
CN103451303B (zh) | 一种pcr法检测人ercc1基因表达水平的试剂盒 | |
Bochkov et al. | EXPERIMENTAL GENETICS Aneuploidy of Stem Cells Isolated from Human Adipose Tissue | |
CN103205400B (zh) | 含有人泛素特异性蛋白酶基因USP39-shRNA的重组慢病毒及其应用 | |
CN109289051B (zh) | Msh2抑制剂在制备逆转mtx耐药肿瘤细胞耐药性的药物中的应用 | |
CN102108369A (zh) | Dna修复蛋白rad51在制备治疗骨肉瘤表达方面的应用 | |
CN110468210A (zh) | Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用 | |
CN104403996A (zh) | 一种具有5-氟尿嘧啶耐药性的人胃癌细胞系及其建立方法和应用 | |
CN110747170A (zh) | 敲减cas的乳腺癌细胞模型及利用其的细胞学实验 | |
CN105582536B (zh) | Agpat9基因在制备治疗肝癌药物、诊断及预后评估试剂中的应用 | |
CN109628601A (zh) | 一种与5-氟尿嘧啶耐药性相关的microRNA分子及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Fu Songbin Inventor after: Meng Xiangning Inventor after: Zhu Jing Inventor after: Li Chunxiang Inventor after: Qi Xiuying Inventor after: Sun Wenjing Inventor after: Zhang Huishu Inventor before: Fu Songbin Inventor before: Meng Xiangning Inventor before: Zhu Jing Inventor before: Li Chunxiang Inventor before: Jin Yan Inventor before: Sun Wenjing Inventor before: Yu Yang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FU SONGBIN MENG XIANGNING ZHU JING LI CHUNXIANG JIN YAN SUN WENJING YU YANG TO: FU SONGBIN MENG XIANGNING ZHU JING LI CHUNXIANG QI XIUYING SUN WENJING ZHANG HUISHU |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |